Future Farm Technologies (CSE:FFT) has announced that Derek Ross has joined as the second member of its Cannabis Advisory Board.
As quoted in the press release:
Mr. Ross has extensive experience in extraction cultivation and the marketing of cannabis. His expert knowledge, extensive background, and industry relationships makes Mr. Ross the perfect strategic addition to the Board, as he will be able to add value on several near term initiatives.
Mr. Ross has over ten years of experience working as a consultant for various non-profit dispensary and cultivation organizations all across the United States. Mr. Ross is the CEO and Founder of Cannatech LLC, a Rhode Island-based cannabis consulting company as well as Cannatech Medicinals, a Massachusetts registered cannabis dispensary. Mr. Ross has been central to the design of controlled environment cultivation facilities for clients, ranging from residential to industrial scale and regularly conducts extensive training seminars and classes on the best practices for fruitful cultivation.
Mr. Ross is also the Founder & President of RCRI Inc., a Rhode Island non-profit business that advocates on behalf of cannabis professionals, patients and caregivers. The company works with legislators, regulators, industry participants on legislation and regulations. Mr. Ross has helped shape the ongoing legal framework for medical cannabis in Rhode Island and is drafting legislation for the recreational cannabis industry.
“We are pleased to welcome Derek Ross to our Cannabis advisory board and look forward to working with him,” says Future Farm’s CEO William Gildea. “Having Derek on our Cannabis Advisory Board will allow us to gain a deeper understanding of the Cannabis business, the state of the market and industry trends. Mr. Ross adds tremendous value for what we are planning in the Northeast market where Mr. Ross is well known.”
The Cannabis Advisory Board will play an important role in Future Farm’s medical cannabis division as it will vet potential business opportunities and partnerships, discover and review value-add organic growth initiatives, and establish new relationships that will help the Company expand its presence within the North American cannabis industry.
Meanwhile, two longstanding cannabis partners ended their relationship.
Trulieve to donate $20,000 in scholarship funding and $15,000 to support leadership development
Trulieve Cannabis Corp . (CSE: TRUL) (OTC: TCNNF), a leading and top-performing cannabis company in the United States today announced a new partnership with the Thurgood Marshall College Fund (TMCF), the nation’s largest organization exclusively representing the Black College Community. Trulieve will donate $20,000 to help fund several college scholarships awarded to students who are attending one of the organization’s member-schools as part of Trulieve’s diversity, equity, and inclusion initiatives. The $15,000 in talent funding is earmarked to support TMCF’s internship program, reaching a diverse talent pool of students and alumni from their 47 member-schools to provide immersive experiences at Trulieve.
The new dispensary expands patient access to Florida’s largest inventory of medical cannabis products
Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 80th nationwide. The new location marks the Company’s first in Tamarac and third in Broward County expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion and Emergency Use Authorization Request
Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild to moderate COVID-19.
With its recent $23 million dollar financing, the Company plans to aggressively expand from 14 clinical sites to up to 50 clinical sites to meet the next enrollment goals for the Study in Q2-2020. The Study is a randomized, double-blinded, placebo-controlled trial and the safety and efficacy data analyzed at each interim analysis timepoint of 210, 400, 600 and 800 completed patients are only made available to the Independent Data and Safety Monitoring Board (“DSMB”) for review and recommendations on continuation, stopping or changes to the conduct of the Study. In the event of any serious safety concerns, the DSMB would be notified to determine any risks and provide its recommendations. To date, in this initial 210 interim point there have been no serious safety concerns that required the DSMB to be notified.
HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) (FWB:8OO) (“HempFusion” or the “Company”), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce that its common shares have been approved for DTC full-service eligibility in the United States by the Depository Trust Company (“DTC”) and can now be both traded and serviced through DTC’s electronic book-entry system.
DTC is a subsidiary of the Depository Trust & Clearing Corp. (“DTCC”) that provides clearing and settlement services for the financial markets and settles the majority of securities transactions in the United States. This electronic method of clearing securities speeds up the receipt of stock and cash and thus accelerates the settlement process for investors and brokers, enabling the stock to be traded over a much wider selection of brokerage firms.